Botulinum toxin type A
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
Conditions
Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
Trial Timeline
Apr 1, 2014 → Sep 4, 2018
NCT ID
NCT02106351About Botulinum toxin type A
Botulinum toxin type A is a phase 3 stage product being developed by Ipsen for Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children. The current trial status is completed. This product is registered under clinical trial identifier NCT02106351. Target conditions include Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children.
What happened to similar drugs?
6 of 14 similar drugs in Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children were approved
Approved (6) Terminated (1) Active (8)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03017729 | Pre-clinical | Completed |
| NCT02969356 | Approved | Completed |
| NCT02020980 | Pre-clinical | Completed |
| NCT02106351 | Phase 3 | Completed |
| NCT01753336 | Phase 3 | Completed |
| NCT01753349 | Pre-clinical | Completed |
| NCT01682148 | Phase 3 | Terminated |
| NCT01313312 | Phase 3 | Completed |
| NCT01251380 | Phase 3 | Completed |
| NCT01251367 | Phase 3 | Completed |
| NCT00455637 | Phase 2 | Terminated |
| NCT00288509 | Phase 3 | Completed |
| NCT00276315 | Phase 3 | Completed |
| NCT00246142 | Phase 3 | Completed |
| NCT00134810 | Phase 2 | Completed |
| NCT00149240 | Phase 2 | Completed |
| NCT00246155 | Phase 3 | Completed |
| NCT00447772 | Phase 3 | Completed |
| NCT00247559 | Phase 2 | Completed |
| NCT00210444 | Phase 2 | Completed |
Competing Products
20 competing products in Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children